期刊
ARCHIVES OF NEUROLOGY
卷 64, 期 10, 页码 1489-1495出版社
AMER MEDICAL ASSOC
DOI: 10.1001/archneur.64.10.1489
关键词
-
资金
- NCRR NIH HHS [U54 RR021813, P41 RR013642, R21 RR019771, RR019771] Funding Source: Medline
- NIA NIH HHS [K23 AG026803, P50 AG016570, P50 AG16570] Funding Source: Medline
- NIBIB NIH HHS [EB01651] Funding Source: Medline
- NIMH NIH HHS [R01 MH071940] Funding Source: Medline
- NLM NIH HHS [LM05639, R01 LM005639] Funding Source: Medline
Background: Alzheimer disease ( AD) is the most common form of dementia worldwide. Mild cognitive impairment (MCI) is the recent terminology for patients with cognitive deficiencies in the absence of functional decline. Most patients with MCI harbor the pathologic changes of AD and demonstrate transition to dementia at a rate of 10% to 15% per year. Patients with AD and MCI experience progressive brain atrophy. Objective: To analyze the structural magnetic resonance imaging data for 24 patients with amnestic MCI and 25 patients with mild AD using an advanced 3-dimensional cortical mapping technique. Design: Cross-sectional cohort design. Patients/Methods: We analyzed the structural magnetic resonance imaging data of 24 amnestic MCI ( mean MMSE, 28.1; SD, 1.7) and 25 mild AD patients (all MMSE scores, > 18; mean MMSE, 23.7; SD, 2.9) using an advanced 3-dimensional cortical mapping technique. Results: We observed significantly greater cortical atrophy in patients with mild AD. The entorhinal cortex, right more than left lateral temporal cortex, right parietal cortex, and bilateral precuneus showed 15% more atrophy and the remainder of the cortex primarily exhibited 10% to 15% more atrophy in patients with mild AD than in patients with amnestic MCI. Conclusion: There are striking cortical differences between mild AD and the immediately preceding cognitive state of amnestic MCI. Cortical areas affected earlier in the disease process are more severely affected than those that are affected late. Our method may prove to be a reliable in vivo disease-tracking technique that can also be used for evaluating disease-modifying therapies in the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据